After decades of hope and hype, this year saw the coming of age of the “magic
bullet” approach to cancer. Glivec, the first “small molecule” cancer therapy,
got the fastest US approval of any cancer drug in history for treating a rare
leukaemia. It proved successful against a stomach cancer, too, and to complete a
busy year it has been granted a British licence. Glivec alone won’t be a miracle
cure for cancer. But with at least six other Glivec-like drugs in trials, each
aimed at a different kind of cancer, it won’t be long before doctors can tailor
treatments to each patient.
To continue reading, today with our introductory offers
Advertisement
More from New Scientist
Explore the latest news, articles and features
Popular articles
Trending New Scientist articles
1
The world's fastest spider tops 3.5 metres per second
2
Where, when and how to watch the 2026 solar eclipse
3
The race to understand how and when Thwaites glacier will collapse
4
Babies are born with the neural foundations for maths
5
This physicist is hunting for the biggest black hole in the universe
6
Our verdict on The Selfish Gene: An unpopular piece of popular science
7
I’m the first person whose life was saved by CRISPR base editing
8
Humans sleep the least of all apes – is it the secret to our success?
9
I have a 100 per cent chance of getting cancer due to a rare gene
10
We’ve uncovered a master gene that switches on human development



